Repositioning Candidate Details
| Candidate ID: | R1605 |
| Source ID: | DB16665 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Idecabtagene vicleucel |
| Synonyms: | Anti-BCMA CAR T cell; IDE-CEL; Idecabtagene vicleucel |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like , a proteasome inhibitor like , or an anti-CD38 monoclonal antibody like . Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like and . These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma. Idecabtagene vicleucel was granted FDA approval on 26 March 2021. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Idecabtagene vicleucel is indicated to treat adult patients with relapsed or refractory multiple myeloma who have tried at least 4 other lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody. |
| DrugBank Pharmacology: | Idecabtagene vicleucel is a B-cell maturation antigen directed chimeric antigen receptor T-cell therapy indicated to treat relapsed or refractory multiple myeloma. It has a long duration of action as expansion takes place over days. Patients should be counselled regarding the risk of hypersensitivity, infection, prolonged cytopenias, hypogammaglobulinemia, secondary malignancies, and to avoid driving for at least 8 weeks after treatment. |
| DrugBank MoA: | Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. The single chain variable fragment (scFv) allows for B-cell maturation antigen specificity of the CAR. The CD23ζ cytoplasmic domain mediates T-cell activation by CD2, a T-cell surface adhesion molecule. 4-1BB enhances cytotoxic T-cell activity as well as the production of interferon-γ. Idecabtagene vicleucel binds to B-cell maturation antigen expressing cells. Binding to the target leads to proliferation of idecabtagene vicleucel, secretion of cytokines, and lysis of the targeted cells. |
| Targets: | Tumor necrosis factor receptor superfamily member 17 binder |
| Inclusion Criteria: | Target associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|